| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Surgery,*Northwestern University Feinberg School of Medicine, Chicago, Illinois; the Eppley Cancer Institute,Omaha, Nebraska; and the Department of Surgery,University of Heidelberg, Heidelberg, Germany
The 5-lipoxygenase (5-LOX) pathway is critical for pancreatic cancer cell growth and escape from apoptosis. Inhibition of 5-LOX blocks proliferation and induces apoptosis in human pancreatic cancer cells. However, the expression of 5-LOX and its downstream signaling pathway have not been investigated in human pancreatic adenocarcinoma. Reverse transcriptase-polymerase chain reaction revealed expression of 5-LOX mRNA in all pancreatic cancer cell lines tested including, PANC-1, AsPC-1, and MiaPaCa2 cells, but not in normal pancreatic ductal cells. The expression of 5-LOX protein in pancreatic cancer cell lines was demonstrated by Western blotting. Finally, 5-LOX up-regulation in human pancreatic cancer tissues was verified by intense positive staining in cancer cells by immunohistochemistry. Staining for the 5-LOX protein was particularly evident in the ductal components of the more differentiated tumors but not in ductal cells in normal pancreatic tissues from cadaver donors. Immunohistochemistry also revealed strong staining of cancer tissues with an antibody to the receptor of the downstream 5-LOX metabolite, leukotriene B4. The current study demonstrated marked expression of 5-LOX and the leukotriene B4 receptor in human pancreatic cancer tissues. These findings provide further evidence of up-regulation of this pathway in pancreatic cancer and that LOX inhibitors are likely to be valuable in the treatment of this dreadful disease.
Related articles in Am J Pathol:
This article has been cited by other articles:
 |
|
 |
|
  B. Sveinbjornsson, A. Rasmuson, N. Baryawno, M. Wan, I. Pettersen, F. Ponthan, A. Orrego, J. Z. Haeggstrom, J. I. Johnsen, and P. Kogner Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy FASEB J, October 1, 2008; 22(10): 3525 - 3536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Rocconi, T. O. Kirby, R. S. Seitz, R. Beck, J. M. Straughn Jr, R. D. Alvarez, and W. K. Huh Lipoxygenase Pathway Receptor Expression in Ovarian Cancer Reproductive Sciences, March 1, 2008; 15(3): 321 - 326. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. Sun, S. Sood, N. Li, D. Ramji, P. Yang, R. A. Newman, C. S. Yang, and X. Chen Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors Carcinogenesis, September 1, 2006; 27(9): 1902 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Schwartz, A. Weitzman, E. O'Reilly, L. Brail, D. P. de Alwis, A. Cleverly, B. Barile-Thiem, V. Vinciguerra, and D. R. Budman Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors J. Clin. Oncol., August 10, 2005; 23(23): 5365 - 5373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hennig, P. Grippo, X.-Z. Ding, S. M. Rao, M. W. Buchler, H. Friess, M. S. Talamonti, R. H. Bell, and T. E. Adrian 5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions Cancer Res., July 15, 2005; 65(14): 6011 - 6016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoque, S. M. Lippman, T.-T. Wu, Y. Xu, Z. D. Liang, S. Swisher, H. Zhang, L. Cao, J. A. Ajani, and X.-c. Xu Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention Carcinogenesis, April 1, 2005; 26(4): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C. S. Yang, and X. Chen Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib Clin. Cancer Res., March 1, 2005; 11(5): 2089 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W.-c. J. Shih, et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis Clin. Cancer Res., October 1, 2004; 10(19): 6703 - 6709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bernstein, C. M. Payne, K. Kunke, C. L. Crowley-Weber, C. N. Waltmire, K. Dvorakova, H. Holubec, C. Bernstein, R. R. Vaillancourt, D. A. Raynes, et al. A proteomic study of resistance to deoxycholate-induced apoptosis Carcinogenesis, May 1, 2004; 25(5): 681 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Nathoo, G H Barnett, and M Golubic The eicosanoid cascade: possible role in gliomas and meningiomas J. Clin. Pathol., January 1, 2004; 57(1): 6 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. ROMANO and J. CLARIA Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy FASEB J, November 1, 2003; 17(14): 1986 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Tong, X.-Z. Ding, R. Hennig, R. C. Witt, J. Standop, P. M. Pour, and T. E. Adrian Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., October 1, 2002; 8(10): 3232 - 3242. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
